Please login to the form below

Not currently logged in
Email:
Password:

Novo Nordisk appoints new senior principal clinical scientist

Stephen Gough joins the Danish diabetes giant
Stephen Gough Novo Nordisk

Novo Nordisk has appointed Stephen Gough as senior principal clinical scientist. 

Gough will be responsible for providing clinical guidance on the development of new molecules and drugs from early stage through to phase III and beyond for obesity and diabetes.

He joins from the Oxford Centre for Diabetes Endocrinology and Metabolism, where he worked with research groups focusing on autoimmunity.

He said: “I am excited to join a company with over 90 years of dedication to finding better treatments for diabetes. 

“I look forward to working with the exceptional scientific team at Novo Nordisk to help translate research into meaningful therapies that makes a difference for patients.”

Alan Moses, CMO of Novo Nordisk, added: “With [Gough's] key clinical expertise, his experience as a researcher focused on patient issues, and his compassion for patients with diabetes, Professor Gough will have a vital role in working toward Novo Nordisk's ambition of changing diabetes.”

1st October 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Origins Insights

Our goal is to identify and embed transformational patient insights as a fundamental part of the drug development process. As...

Latest intelligence

What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...